tert-butyl (S)-(1-(4-chlorophenyl)-3-oxopropan-2-yl)carbamate | 322392-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (S)-(1-(4-chlorophenyl)-3-oxopropan-2-yl)carbamate
• 英文别名: tert-butyl N-[(2S)-1-(4-chlorophenyl)-3-oxopropan-2-yl]carbamate
• CAS: 322392-25-6
• 化学式: C₁₄H₁₈ClNO₃
• 分子量: 283.755
• InChiKey: COZIUWDTRVBHAB-LBPRGKRZSA-N

物化性质

• 沸点：
  394.1±37.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-(1-(4-chlorophenyl)-3-oxopropan-2-yl)carbamate 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 Dodecanoic acid {(S)-1-[(S)-1-(4-chloro-benzyl)-2-ethylcarbamoyl-2-hydroxy-ethylcarbamoyl]-2-methyl-propyl}-amide
  参考文献：
  名称：

  Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

  摘要：

  Dipeptide-derived alpha-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.064
• 作为产物：
  描述：

  BOC-L-4-氯苯丙氨酸 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 tert-butyl (S)-(1-(4-chlorophenyl)-3-oxopropan-2-yl)carbamate
  参考文献：
  名称：

  Novel cell-penetrating α-keto-amide calpain inhibitors as potential treatment for muscular dystrophy

  摘要：

  Dipeptide-derived alpha-keto-amide compounds with potent calpain inhibitory activity have been identified. These reversible covalent inhibitors have IC50 values down to 25 nM and exhibit greatly improved activity in muscle cells compared to the reference compound MDL28170. Several novel calpain inhibitors have shown positive effects on histological parameters in an animal model of Duchenne muscular dystrophy demonstrating their potential as a treatment option for this fatal disease. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.08.064

文献信息

• [EN] SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE CHITINASE HUMAINE
  申请人：ONCOARENDI THERAPEUTICS SP Z O O

  公开号：WO2017037670A1

  公开（公告）日：2017-03-09

  Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

  揭示了一种氨基三唑化合物，其带有一个被杂环环取代的哌啶环。这些化合物是酸性哺乳动物几丁质酶和几丁三糖酶的抑制剂。还公开了使用这些化合物治疗由过敏原引起的哮喘反应，以及急性和慢性炎症性疾病、自身免疫疾病、牙科疾病、神经系统疾病、代谢性疾病、肝脏疾病、多囊卵巢综合征、子宫内膜异位症和癌症的方法。
• [EN] SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS<br/>[FR] DERIVES DE PIPERIDINE ET DE PIPERAZINE SUBSTITUES UTILISES EN TANT QUE MODULATEURS DU RECEPTEUR DE LA MELANOCORTINE-4
  申请人：MYOCONTRACT LTD

  公开号：WO2004083208A1

  公开（公告）日：2004-09-30

  The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.

  本发明涉及一种新型的替代哌啶和哌嗪衍生物，作为黑色素皮质素-4受体（MC-4R）调节剂。本发明的MC-4R激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而MC-4R拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。所有涉及MC-4R调节的疾病和障碍均可使用本发明的化合物治疗。
• Alpha-Keto carbonyl calpain inhibitors
  申请人：MyoContract Ltd.

  公开号：EP1454627A1

  公开（公告）日：2004-09-08

  The present invention relates to novel α-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Generally all conditions where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease (MCP) also known as proteasome may also be inhibited. The compounds of the present invention are also inhibitors of cell damage by oxidative stress through free radicals and can be used to treat mitochondrial disorders and neurodegenerative diseases, where elevated levels of oxidative stress are involved.

  本发明涉及用于治疗神经退行性疾病和神经肌肉疾病，包括杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症和其他肌肉萎缩症的新型α-酮羰基卡尔宁抑制剂。也可以治疗运动不足性萎缩和一般肌肉消耗。通常，所有涉及卡尔宁升高水平的情况都可以得到治疗。本发明的化合物还可以抑制其他硫醇蛋白酶，如卡特普辛B、卡特普辛H、卡特普辛L、木瓜蛋白酶等。多催化蛋白酶（MCP），也称为蛋白酶体，也可以被抑制。本发明的化合物还是通过自由基抑制氧化应激引起的细胞损伤的抑制剂，并可用于治疗涉及氧化应激升高水平的线粒体疾病和神经退行性疾病。
• Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators
  申请人：MyoContract Ltd.

  公开号：EP1460069A1

  公开（公告）日：2004-09-22

  The present invention relates to novel substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及新型取代环己基和哌啶基衍生物，作为黑色素皮质激素-4受体（MC-4R）调节剂。本发明的MC-4R激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而MC-4R拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。所有需要MC-4R调节的疾病和障碍都可以用本发明的化合物进行治疗。
• SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS
  申请人：OncoArendi Therapeutics Sp. z o.o.

  公开号：US20170066743A1

  公开（公告）日：2017-03-09

  Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer.

  本发明涉及一种氨基三唑化合物，其被取代为带有杂环环的哌啶环。这些化合物是酸性哺乳动物几丁质酶和几丁三糖酶的抑制剂。本发明还涉及使用这些化合物治疗由过敏原引起的哮喘反应，以及急性和慢性炎症性疾病、自身免疫疾病、牙科疾病、神经疾病、代谢性疾病、肝脏疾病、多囊卵巢综合症、子宫内膜异位症和癌症的方法。